SG10201810093PA - Pharmaceutical composition for external use - Google Patents

Pharmaceutical composition for external use

Info

Publication number
SG10201810093PA
SG10201810093PA SG10201810093PA SG10201810093PA SG10201810093PA SG 10201810093P A SG10201810093P A SG 10201810093PA SG 10201810093P A SG10201810093P A SG 10201810093PA SG 10201810093P A SG10201810093P A SG 10201810093PA SG 10201810093P A SG10201810093P A SG 10201810093PA
Authority
SG
Singapore
Prior art keywords
external use
pharmaceutical composition
tocopherol
derivative
diclofenac
Prior art date
Application number
SG10201810093PA
Inventor
Kazuyoshi Ado
Kozue Imai
Original Assignee
Kobayashi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co Ltd filed Critical Kobayashi Pharmaceutical Co Ltd
Publication of SG10201810093PA publication Critical patent/SG10201810093PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

PharmaceuticalComposition for External Use [Problem to be Solved] An object of the present invention is to provide a formulation technique that can suppress cloudiness and the formation of precipitate to provide excellent appearance characteristics, while incorporating diclofenac and a tocopherol and/or a derivative thereof into a pharmaceutical composition for external use containing water. [Solution] When menthol is blended into a pharmaceutical composition for external use containing diclofenac and/or a salt thereof, a tocopherol and/or a derivative thereof, and water, cloudiness and the formation of precipitate due to diclofenac and/or a salt thereof and a tocopherol and/or a derivative thereof can be suppressed, and excellent appearance characteristics can be provided in the pharmaceutical composition for external use. / 22 NoSuitableFigure
SG10201810093PA 2014-03-30 2015-03-26 Pharmaceutical composition for external use SG10201810093PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014070678A JP6580305B2 (en) 2014-03-30 2014-03-30 Pharmaceutical composition for external use

Publications (1)

Publication Number Publication Date
SG10201810093PA true SG10201810093PA (en) 2018-12-28

Family

ID=54240316

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201810093PA SG10201810093PA (en) 2014-03-30 2015-03-26 Pharmaceutical composition for external use
SG11201608123VA SG11201608123VA (en) 2014-03-30 2015-03-26 Pharmaceutical composition for external use

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201608123VA SG11201608123VA (en) 2014-03-30 2015-03-26 Pharmaceutical composition for external use

Country Status (6)

Country Link
JP (1) JP6580305B2 (en)
CN (1) CN106456598B (en)
MY (1) MY182059A (en)
SG (2) SG10201810093PA (en)
TW (1) TWI712408B (en)
WO (1) WO2015151990A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7086596B2 (en) * 2017-12-28 2022-06-20 小林製薬株式会社 External composition
JP7086597B2 (en) * 2017-12-28 2022-06-20 小林製薬株式会社 External composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5976013A (en) * 1982-10-23 1984-04-28 Toko Yakuhin Kogyo Kk Gelatinous pharmaceutical for surgical use
JP3044352B2 (en) * 1989-11-20 2000-05-22 ライオン株式会社 Patch
CA2058975C (en) * 1990-10-30 2000-06-06 Shuichi Kasai Antiinflammatory gel preparation
JP3100408B2 (en) * 1991-03-26 2000-10-16 株式会社資生堂 Skin external preparation containing diclofenac sodium
JPH11255644A (en) * 1998-03-09 1999-09-21 Lintec Corp Percutaneous absorption type antipyretic antiphlogistic analgesic
US7138394B2 (en) * 2002-09-27 2006-11-21 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
JP4820065B2 (en) * 2004-05-24 2011-11-24 同仁医薬化工株式会社 Anti-inflammatory analgesic topical aqueous solution
PE20060935A1 (en) * 2004-10-21 2006-10-26 Novartis Ag PHARMACEUTICAL COMPOSITION INCLUDING DICLOFENACO
CH699814B1 (en) * 2007-05-14 2010-05-14 Mepha Ag Diclofenac for topical application as a spray.
KR101517494B1 (en) * 2007-06-08 2015-05-04 트로이카 파마슈티칼스 리미티드 A novel non-aqueous topical solution of diclofenac and process for preparing the same
MX2011008095A (en) * 2009-01-30 2012-01-27 Kydes Pharmaceuticals Llc Transdermal delivery of diclofenac, carbamazepine and benzydamine.
JP5421063B2 (en) * 2009-10-23 2014-02-19 帝國製薬株式会社 Diclofenac sodium-containing aqueous patch
EP2753319B1 (en) * 2011-09-09 2018-04-11 Vizuri Health Sciences LLC A pain relief composition, comprising a trpv1 selective agonist, and manufacture and uses thereof
JP6738120B2 (en) * 2013-03-29 2020-08-12 小林製薬株式会社 External pharmaceutical composition

Also Published As

Publication number Publication date
WO2015151990A1 (en) 2015-10-08
TWI712408B (en) 2020-12-11
SG11201608123VA (en) 2016-11-29
JP6580305B2 (en) 2019-09-25
MY182059A (en) 2021-01-18
JP2015189760A (en) 2015-11-02
CN106456598B (en) 2020-06-02
CN106456598A (en) 2017-02-22
TW201622712A (en) 2016-07-01

Similar Documents

Publication Publication Date Title
MX2016016666A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2015008628A (en) Boronic acid derivatives and therapeutic uses thereof.
MX364486B (en) Pyridazinone-amides derivatives.
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX370792B (en) Methods and compositions for the treatment of cancer.
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
NZ745811A (en) Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid
SA517381678B1 (en) Dihydropyrimidin-2-One Compounds and Medical Use Thereof
NZ730790A (en) Composition of (6s)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PH12018501709A1 (en) Naphthridinedione derivatives
IN2014DN11078A (en)
MX2018007112A (en) Fast dissolving peroxymonosulfate composition.
MX2016004909A (en) Composition containing eugenol as active ingredient for preventing or treating atopic dermatitis.
MX2015013755A (en) Pharmaceutical formulation for use in the treatment and/or prevention of restenosis.
MX355668B (en) Use of a myrtle extract as an anti-biofilm agent against p. acnes.
SG10201810093PA (en) Pharmaceutical composition for external use
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
MX2016006742A (en) Pharmaceutical composition.
MY192061A (en) Pharmaceutical composition for external use
EA201500446A1 (en) PHARMACEUTICAL COMPOSITION TO REDUCE N-OXIDE TRIMETYLAMINE LEVEL
PH12016501647B1 (en) Oral liquid vitamin supplements containing zinc and estabilized vitamin c with reduced astringency